Major drug safety watch launched for 600 korean IBD patients
NCT ID NCT05428345
Summary
This study is monitoring the safety and real-world effectiveness of vedolizumab injections in 600 Korean adults with ulcerative colitis or Crohn's disease. Participants have already tried other treatments without success and are receiving vedolizumab as part of their regular care. Researchers will collect health data for approximately 6 years to track side effects and how well the treatment controls symptoms and promotes healing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Donggguk University Ilsan Hospital
RECRUITINGGoyang-si, Gyeonggi-do, 10326, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.